

## Research Income 2018-2023

| Research External Income Sources                          |         |         |         |         |         |
|---|---------|---------|---------|---------|---------|
| Source  | 2018/19 | 2019/20 | 2020/21 | 2021/22 | 2022/23 |
|   |         |         |         |         |         |
| Clinical Research Network Core Funding                    | 400,000 | 420,000 | 445,000 | 463,000 | 477,000 |
| Clinical Research Network Contingency Funding             | 39,413  | 5,000   | 0       | 35,424  | 52,158  |
| Greenshoots Funding                                       | 0       | 13,358  | 0       | 0       | 0       |
| Excess Treatment Costs Payments                           | 0       | 3,106   | 352     | 9,293   | 3,807   |
| Research Capability Funding                               | 20,000  | 20,000  | 52,960  | 48,054  | 29,073  |
| Commercial and non-commercial research Income             | 10,453  | 2,414   | 3,457   | 35,123  | 46,964  |
|   |         |         |         |         |         |
| Other Funding   |         |         |         |         |         |
| Hosted NIHR Grant (IBER)                                  | 5,258   | 150,353 | 63,279  | 26,555  | 0       |
| Non-commercial funding via a NIHR grant (STADIA)          | 0       | 7,003   | 11,554  | 6,420   | 15,338  |
| Hosted NIHR Grant (ASCEND)                                | 0       | 2,755   | 151,125 | 117,133 | 0       |
| Doctoral Research Fellowship                              | 0       | 0       | 3,171   | 109,273 | 0       |
| Hosted NIHR Grant (iPOF Online Mental Health Communities) | 0       | 0       | 0       | 0       | 337,801 |
| MSK Physio Internship funding                             | 0       | 0       | 0       | 0       | 9,219   |
|   |         |         |         |         |         |
| Totals  | 475,124 | 623,989 | 730,898 | 850,276 | 971,360 |

| 2022/23               | £      |
|-----------------------|--------|
| NEFERTITI             | 26,508 |
| IVY Study             | 14,490 |
| Multicath             | 2,279  |
| Novavax Vaccine trial | 1,866  |
| HIS UK                | 965    |
| SafePIT               | 770    |
| Eye 2                 | 46     |
| ADDRESS-2             | 40     |
| Total 2022/23         | 46,964 |

| 2021/22             | £      |
|---------------------|--------|
|                     |        |
| PrEP Impact Trial   | 27,322 |
| Fluenz Tetra        | 2,715  |
| NEFERTITI           | 1,350  |
| Deep Learning Study | 1,350  |
| Activation Study    | 1,350  |
| Real World Barriers | 337    |
| ADDRESS-2           | 320    |



| EMPA-VISION PIC      | 250    |
|----------------------|--------|
| Hearing Nasty Voices | 75     |
| Measuring Outcomes   | 54     |
| Total 2021/22        | 35,123 |

| 2020/21                             |       |
|-------------------------------------|-------|
| PPiP2 Research Study                | 210   |
| Exploring Unusual Feelings Research | 275   |
| IDEAL project                       | 1,953 |
| Clarity-AD                          | 1,019 |
|                                     |       |
| Total 2020/21                       | 3,457 |

| 2019/20              |       |
|----------------------|-------|
| Scimitar+ Study      | 30    |
| IDEAL project        | 1,581 |
| PrEP Impact Trial    | 517   |
| PPiP2 Research Study | 220   |
| Safetxt Study        | 66    |
|                      |       |
| Total 2019/20        | 2,414 |

| Total 2018/19                             | 10,453 |
|---|--------|
| Dementia                                  | 1,650  |
| Insulin Management for people living with |        |
| Safetxt Study                             | 209    |
| Fluenz                                    | 1,000  |
| Pharmacy Trial Management                 | 500    |
| PrEP Impact Trial                         | 1,607  |
| IDEAL project                             | 5,487  |
| 2018/19                                   |        |